ストックスクリーナーアプリを入手
1.69
6.11%
-0.11
前日終値:
$1.80
開ける：
$1.79
24時間の取引高:
152.06K
Relative Volume:
0.14
時価総額：
$9.18M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+2.42%
1か月 パフォーマンス:
+38.52%
6か月 パフォーマンス:
-63.66%
1年 パフォーマンス:
-89.21%
1日の値動き範囲:
$1.67
$1.79
1週間の範囲:
$1.60
$1.95
52週間の値動き範囲:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
TRAW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.69 | 9.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-18 | 開始されました | Guggenheim | Buy |
| 2018-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-09 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-27 | 開始されました | Laidlaw | Buy |
| 2015-07-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Traws Pharma Inc (TRAW) 最新ニュース
Millennium Management LLC Buys New Holdings in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer - MSN
Traws Pharma (NASDAQ:TRAW) Trading 0.6% Higher – Here’s What Happened - Defense World
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MSN
Traws Pharma Inc. Stock Skyrockets Over 40%, Then Pares Gains in Volatile Trading - Daily Chhattisgarh News
Traws Pharma Stock (TRAW) Surges 55% on Positive Cancer Data - TipRanks
Traws Pharma (TRAW) Releases Promising Clinical Trial Results fo - GuruFocus
Traws Pharma Publishes Promising Phase 2 Study Results - TipRanks
Traws Pharma Announces Publication of Compelling Efficacy - GlobeNewswire
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - GlobeNewswire Inc.
Traws Pharma Receives FDA Feedback on Flu Drug Development - MSN
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir - GlobeNewswire
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness - marketscreener.com
Traws Pharma advances flu drug development with FDA feedback - Investing.com India
Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic Preparedness - marketscreener.com
Traws Pharma Receives FDA Guidance on Flu Treatment - TipRanks
Traws Pharma (TRAW) Gains FDA Insights on Flu Treatment Pathway | TRAW Stock News - GuruFocus
Traws Pharma advances flu drug development with FDA feedback By Investing.com - Investing.com Nigeria
FDA Advances Critical Bird Flu Drug Development as Ex-CDC Chief Warns of 50% Death Rate Risk - Stock Titan
Traws Pharma Unveils New Strategic Antiviral Focus - TipRanks
Traws Pharma’s Q1 2025 Results Highlight Progress and Profit - TipRanks
Traws Pharma Reports First Quarter 2025 Results And Business Highlights - marketscreener.com
Traws Pharma Reports Q1 2025 Financial Results - TipRanks
Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewswire
Traws Pharma Earnings Surge to $21.5M as Former CDC Director Backs Novel Flu and COVID Drug Pipeline - Stock Titan
Renaissance Technologies LLC Takes $89,000 Position in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Geode Capital Management LLC Makes New $185,000 Investment in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
TRAWTraws Pharma Latest Stock News & Market Updates - Stock Titan
TRAW stock touches 52-week low at $1.51 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $1.51 amid sharp annual decline - Investing.com India
Traws Pharma Appoints New Chairman Amid Leadership Changes - MSN
Traws Pharma appoints new interim CEO with compensation details By Investing.com - Investing.com Canada
Traws Pharma appoints new interim CEO with compensation details - Investing.com Australia
Traws Pharma announces $50 million stock offering potential - Investing.com Australia
Traws Pharma announces $50 million stock offering potential By Investing.com - Investing.com Canada
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Traws Pharma Inc (TRAW) 財務データ
Traws Pharma Inc (TRAW) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):